nach oben

European Journal of Nutrition

Erschienen in:

20.09.2018 | Original Contribution

Effects of products designed to modulate the gut microbiota on hyperlipidaemia

verfasst von: Xilong Deng, Jie Ma, Meiting Song, Ye Jin, Cheng Ji, Weihong Ge, Changrun Guo

Erschienen in: European Journal of Nutrition | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Fatalities due to heart and cerebrovascular diseases caused by uncontrolled hyperlipidaemia increase every year; on the other hand, lipid-lowering drugs are known to cause side effects. The gut microbiota has been thoroughly investigated by researchers and consumers, because they have unique functional properties and littler side effects. However, the effects of the gut microbiota remain controversial. We conducted a meta-analysis to assess the effects of products designed to modulate the gut microbiota on various hyperlipidaemias.

Methods

We systematically searched PubMed, Embase, Cochrane Library (Central), and Web of Science for randomized controlled trials (published before June 2017, and those only in English) to compare treatment (products designed to modulate the gut microbiota) versus placebo. Our main endpoints were total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) in serum. We assessed pooled data using a fixed effects model.

Results

Of 1337 identified studies, 21 were eligible and included in our analysis (n = 1436 participants). The combined estimate of effect size for the impact of products designed to modulate the gut microbiota on serum TC (WMD − 11.07 mg/dL, 95% CI − 13.72 to − 8.43, p < 0.001), LDL-C (WMD − 10.96 mg/dL, 95% CI − 13.37 to − 8.56, p < 0.001), and HDL-C (WMD 0.72 mg/dL, 95% CI 0.06–1.38, p = 0.032) were statistically significant, while no significant effect was found on TG concentrations (WMD − 0.56 mg/dL, 95% CI − 5.59 to 4.47, p = 0.828). Subgroup analysis showed parallel trials, probiotics, and long-term intervention had better effects on lowering blood lipid levels.

Conclusion

Products designed to modulate the gut microbiota results in changes of the plasma lipid concentrations and these changes may protect against cardiovascular disease.

Nur mit Berechtigung zugänglich

Owens AP, Byrnes JR, Mackman N (2014) Hyperlipidemia, tissue factor, coagulation, and simvastatin. Trends Cardiovasc Med 24(3):95–98. https://doi.org/10.1016/j.tcm.2013.07.003 CrossRefPubMed

Mitchell S, Roso S, Samuel M, Pladevall-Vila M (2016) Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies. BMC Cardiovasc Disord 16(1):74–84. https://doi.org/10.1186/s12872-016-0241-3 CrossRefPubMedPubMedCentral

Committee of Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults (2016) Chinese guidelines on prevention and treatment of dyslipidemia in adults. Chin Circ J 31(10):937–953. https://doi.org/10.3969/j.issn.1000-3614.2016.10.001 CrossRef

Obesity CRi (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106(25):3143–3421CrossRef

Abel ED, Litwin SE, Sweeney G (2008) Cardiac remodeling in obesity. Physiol Rev 88(2):389–419. https://doi.org/10.1152/physrev.00017.2007 CrossRefPubMedPubMedCentral

Wang Y, Liu D, Li Y, Guo L, Cui Y, Zhang X, Li E (2016) Metabolomic analysis of serum from obese adults with hyperlipemia by UHPLC-Q-TOF MS/MS. Biomed Chromatogr 30(1):48–54. https://doi.org/10.1002/bmc.3491 CrossRefPubMed

Chen Y-L, Xiao C-H, Hu Z-X, Liu X-S, Liu Z, Zhang W-N, Zhao X-J (2017) Dynamic lipid profile of hyperlipidemia mice. J Chromatogr B 1055–1056:165–171. https://doi.org/10.1016/j.jchromb.2017.04.017 CrossRef

Taylor BL, Woodfall GE, Sheedy KE, O’Riley ML, Rainbow KA, Bramwell EL, Kellow NJ (2017) Effect of probiotics on metabolic outcomes in pregnant women with gestational diabetes: a systematic review and meta-analysis of randomized controlled trials. Nutrients 9(5):461–474. https://doi.org/10.3390/nu9050461 CrossRefPubMedCentral

Flint HJ, Scott KP, Louis P, Duncan SH (2012) The role of the gut microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol 9(10):577–589CrossRef

10.

Sanders Mary E (2008) Probiotics: definition, sources, selection, and uses. Clin Infect Dis 46(s2):S58–S61. https://doi.org/10.1086/523341 CrossRefPubMed

11.

Gourbeyre P, Denery S, Bodinier M (2011) Probiotics, prebiotics, and synbiotics: impact on the gut immune system and allergic reactions. J Leukoc Biol 89(5):685–695. https://doi.org/10.1189/jlb.1109753 CrossRefPubMed

12.

Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR, Delzenne NM (2007) Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50(11):2374–2383. https://doi.org/10.1007/s00125-007-0791-0 CrossRefPubMed

13.

Nicolucci AC, Reimer RA (2017) Prebiotics as a modulator of gut microbiota in paediatric obesity. Pediatr Obes 12(4):265–273. https://doi.org/10.1111/ijpo.12140 CrossRefPubMed

14.

Bagarolli RA, Tobar N, Oliveira AG, Araújo TG, Carvalho BM, Rocha GZ, Vecina JF, Calisto K, Guadagnini D, Prada PO, Santos A, Saad STO, Saad MJA (2017) Probiotics modulate gut microbiota and improve insulin sensitivity in DIO mice. J Nutr Biochem 50:16–25. https://doi.org/10.1016/j.jnutbio.2017.08.006 CrossRefPubMed

15.

Wang Y, Sun J, Zhong H, Li N, Xu H, Zhu Q, Liu Y (2017) Effect of probiotics on the meat flavour and gut microbiota of chicken. Sci Rep. https://doi.org/10.1038/s41598-017-06677-z CrossRefPubMedPubMedCentral

16.

De Roos NM, Scheuten G, Katan MB (1999) Yoghurt enriched with Lactobacillus acidophilus does not lower blood lipids in healthy men and women with normal to borderline high serum cholesterol levels. Eur J Clin Nutr 53(4):277–280CrossRef

17.

Lewis SJ, Burmeister S (2005) A double-blind placebo-controlled study of the effects of Lactobacillus acidophilus on plasma lipids. Eur J Clin Nutr 59(6):776–780. https://doi.org/10.1038/sj.ejcn.1602139 CrossRefPubMed

18.

Simons LA, Amansec SG, Conway P (2006) Effect of Lactobacillus fermentum on serum lipids in subjects with elevated serum cholesterol. Nutr Metabol Cardiovasc Dis 16(8):531–535. https://doi.org/10.1016/j.numecd.2005.10.009 CrossRef

19.

Andrade S, Borges N (2009) Effect of fermented milk containing Lactobacillus acidophilus and Bifidobacterium longum on plasma lipids of women with normal or moderately elevated cholesterol. J Dairy Res 76(4):469–474. https://doi.org/10.1017/S0022029909990173 CrossRefPubMed

20.

Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V, Akbarian-Moghari A (2011) Effect of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium lactis on lipid profile in individuals with type 2 diabetes mellitus. J Dairy Sci 94(7):3288–3294. https://doi.org/10.3168/jds.2010-4128 CrossRefPubMed

21.

Asemi Z, Samimi M, Tabasi Z, Talebian P, Azarbad Z, Hydarzadeh Z, Esmaillzadeh A (2012) Effect of daily consumption of probiotic yoghurt on lipid profiles in pregnant women: a randomized controlled clinical trial. J Mater Fetal Neonatal Med 25 (9):1552–1556. https://doi.org/10.3109/14767058.2011.640372 CrossRef

22.

Jones ML, Martoni CJ, Parent M, Prakash S (2012) Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. Br J Nutr 107(10):1505–1513. https://doi.org/10.1017/S0007114511004703 CrossRefPubMed

23.

Agerholm-Larsen LBM, Grunwald GK, Astrup A (2000) The effect of a probiotic milk product on plasma cholesterol: a meta-analysis of short-term intervention studies. Eur J Clin Nutr 54:856–860CrossRef

24.

Guo Z, Liu XM, Zhang QX, Shen Z, Tian FW, Zhang H, Sun ZH, Zhang HP, Chen W (2011) Influence of consumption of probiotics on the plasma lipid profile: a meta-analysis of randomised controlled trials. Nutr Metabol Cardiovasc Dis 21(11):844–850. https://doi.org/10.1016/j.numecd.2011.04.008 CrossRef

25.

Cho YA, Kim J (2015) Effect of probiotics on blood lipid concentrations a meta-analysis of randomized controlled trials. Medicine 94(43):e1714–e1724. https://doi.org/10.1097/md.0000000000001714 CrossRefPubMedPubMedCentral

26.

Shimizu M, Hashiguchi M, Shiga T, Tamura HO, Mochizuki M (2015) Meta-Analysis: Effects of probiotic supplementation on lipid profiles in normal to mildly hypercholesterolemic individuals. PLoS One 10(10):e0139795. https://doi.org/10.1371/journal.pone.0139795 CrossRefPubMedPubMedCentral

27.

Puri S, Sharma S, Kurpad A (2016) Potential of probiotics in hypercholesterolemia: a meta-analysis. Indian J Pub Health 60(4):280–286. https://doi.org/10.4103/0019-557x.195859 CrossRef

28.

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62(10):1006–1012. https://doi.org/10.1016/j.jclinepi.2009.06.005 CrossRefPubMed

29.

Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56(2):455–463CrossRef

30.

Wang Y, Ames NP, Tun HM, Tosh SM, Jones PJ, Khafipour E (2016) High molecular weight barley β-glucan alters gut microbiota toward reduced cardiovascular disease risk. Front Microbiol 7:129–144. https://doi.org/10.3389/fmicb.2016.00129 CrossRefPubMedPubMedCentral

31.

Larkin TA, Astheimer LB, Price WE (2009) Dietary combination of soy with a probiotic or prebiotic food significantly reduces total and LDL cholesterol in mildly hypercholesterolaemic subjects. Eur J Clin Nutr 63(2):238–245. https://doi.org/10.1038/sj.ejcn.1602910 CrossRefPubMed

32.

Bertolami MC, Faludi AA, Batlouni M (1999) Evaluation of the effects of a new fermented milk product (Gaio) on primary hypercholesterolemia. Eur J Clin Nutr 53(2):97–101CrossRef

33.

Kiessling G, Schneider J, Jahreis G (2002) Long-term consumption of fermented dairy products over 6 months increases HDL cholesterol. Eur J Clin Nutr 56(9):843–849. https://doi.org/10.1038/sj.ejcn.1601399 CrossRefPubMed

34.

St-Onge MP, Farnworth ER, Savard T, Chabot D, Mafu A, Jones PJ (2002) Kefir consumption does not alter plasma lipid levels or cholesterol fractional synthesis rates relative to milk in hyperlipidemic men: a randomized controlled trial. BMC Complement Altern Med 2:1–7CrossRef

35.

Xiao JZ, Kondo S, Takahashi N, Miyaji K, Oshida K, Hiramatsu A, Iwatsuki K, Kokubo S, Hosono A (2003) Effects of milk products fermented by Bifidobacterium longum on blood lipids in rats and healthy adult male volunteers. J Dairy Sci 86(7):2452–2461CrossRef

36.

Giacco R, Clemente G, Luongo D, Lasorella G, Fiume I, Brouns F, Bornet F, Patti L, Cipriano P, Rivellese AA, Riccardi G (2004) Effects of short-chain fructo-oligosaccharides on glucose and lipid metabolism in mild hypercholesterolaemic individuals. Clin Nutr 23(3):331–340. https://doi.org/10.1016/j.clnu.2003.07.010 CrossRefPubMed

37.

Hlivak P, Odraska J, Ferencik M, Ebringer L, Jahnova E, Mikes Z (2005) One-year application of probiotic strain Enterococcus faecium M-74 decreases serum cholesterol levels. Bratislavské lekárske listy 106(2):67–72PubMed

38.

Hatakka K, Mutanen M, Holma R, Saxelin M, Korpela R (2008) Lactobacillus rhamnosus LC705 together with Propionibacterium freudenreichii ssp shermanii JS administered in capsules is ineffective in lowering serum lipids. J Am Coll Nutr 27(4):441–447CrossRef

39.

Ataie-Jafari A, Larijani B, Alavi Majd H, Tahbaz F (2009) Cholesterol-lowering effect of probiotic yogurt in comparison with ordinary yogurt in mildly to moderately hypercholesterolemic subjects. Ann Nutr Metabol 54(1):22–27. https://doi.org/10.1159/000203284 CrossRef

40.

Ooi LG, Ahmad R, Yuen KH, Liong MT (2010) Lactobacillus acidophilus CHO-220 and inulin reduced plasma total cholesterol and low-density lipoprotein cholesterol via alteration of lipid transporters. J Dairy Sci 93(11):5048–5058. https://doi.org/10.3168/jds.2010-3311 CrossRefPubMed

41.

Berthold HK, Schulte DM, Lapointe JF, Lemieux P, Krone W, Gouni-Berthold I (2011) The whey fermentation product malleable protein matrix decreases triglyceride concentrations in subjects with hypercholesterolemia: a randomized placebo-controlled trial1. J Dairy Sci 94(2):589–601. https://doi.org/10.3168/jds.2010-3115 CrossRefPubMed

42.

Jones ML, Martoni CJ, Prakash S (2012) Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. Eur J Clin Nutr 66(11):1234–1241. https://doi.org/10.1038/ejcn.2012.126 CrossRefPubMed

43.

Fuentes MC, Lajo T, Carrion JM, Cune J (2013) Cholesterol-lowering efficacy of Lactobacillus plantarum CECT 7527, 7528 and 7529 in hypercholesterolaemic adults. Br J Nutr 109(10):1866–1872. https://doi.org/10.1017/s000711451200373x CrossRefPubMed

44.

Ogawa A, Kadooka Y, Kato K, Shirouchi B, Sato M (2014) Lactobacillus gasseri SBT2055 reduces postprandial and fasting serum non-esterified fatty acid levels in Japanese hypertriacylglycerolemic subjects. Lipids Health Dis 13:36–44. https://doi.org/10.1186/1476-511x-13-36 CrossRefPubMedPubMedCentral

45.

Ahn HY, Kim M, Ahn YT, Sim JH, Choi ID, Lee SH, Lee JH (2015) The triglyceride-lowering effect of supplementation with dual probiotic strains, Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032: reduction of fasting plasma lysophosphatidylcholines in nondiabetic and hypertriglyceridemic subjects. Nutr Metabol Cardiovasc Dis 25(8):724–733. https://doi.org/10.1016/j.numecd.2015.05.002 CrossRef

46.

Rerksuppaphol S, Rerksuppaphol L (2015) A randomized double-blind controlled trial of Lactobacillus acidophilus plus bifidobacterium bifidum versus placebo in patients with hypercholesterolemia. J Clin Diagn Res 9(3):KC01–K04. https://doi.org/10.7860/JCDR/2015/11867.5728 CrossRefPubMedPubMedCentral

47.

Cavallini DC, Manzoni MS, Bedani R, Roselino MN, Celiberto LS, Vendramini RC, de Valdez G, Abdalla DS, Pinto RA, Rosetto D, Valentini SR, Rossi EA (2016) Probiotic soy product supplemented with isoflavones improves the lipid profile of moderately hypercholesterolemic men: a randomized controlled trial. Nutrients 8(1):52–70. https://doi.org/10.3390/nu8010052 CrossRef

48.

Fuentes MC, Lajo T, Carrion JM, Cune J (2016) A randomized clinical trial evaluating a proprietary mixture of Lactobacillus plantarum strains for lowering cholesterol. Mediterr J Nutr Metabol 9(2):125–135. https://doi.org/10.3233/MNM-160065 CrossRef

49.

Tan S, Zhao A, Zheng Y, Wang P, Zhang Y (2017) Effects of Lactobacillus paracasei N1115 on intestinal microbiota and serum lipid of dyslipidemias. FASEB J 31 (1 Supplement):45–46

50.

Gilliland SE, Nelson CR, Maxwell C (1985) Assimilation of cholesterol by Lactobacillus acidophilus. Appl Environ Microbiol 49(2):377–381PubMedPubMedCentral

51.

Pereira DI, Gibson GR (2002) Cholesterol assimilation by lactic acid bacteria and bifidobacteria isolated from the human gut. Appl Environ Microbiol 68(9):4689–4693CrossRef

52.

Liong MT, Shah NP (2005) Bile salt deconjugation and BSH activity of five bifidobacterial strains and their cholesterol co-precipitating properties. Food Res Int 38(2):135–142. https://doi.org/10.1016/j.foodres.2004.08.003 CrossRef

53.

Tahri K, Grill JP, Schneider F (1997) Involvement of trihydroxyconjugated bile salts in cholesterol assimilation by bifidobacteria. Curr Microbiol 34(2):79–84CrossRef

54.

Zhao JR, Yang H (2005) Progress in the effect of probiotics on cholesterol and its mechanism. Wei sheng wu xue bao = Acta microbiologica Sinica 45(2):315–319PubMed

55.

Huang Y, Zheng Y (2010) The probiotic Lactobacillus acidophilus reduces cholesterol absorption through the down-regulation of Niemann-Pick C1-like 1 in Caco-2 cells. Br J Nutr 103(4):473–478. https://doi.org/10.1017/s0007114509991991 CrossRefPubMed

56.

Lye H-S, Rahmat-Ali GR, Liong M-T (2010) Mechanisms of cholesterol removal by lactobacilli under conditions that mimic the human gastrointestinal tract. Int Dairy J 20(3):169–175. https://doi.org/10.1016/j.idairyj.2009.10.003 CrossRef

57.

Sterne JA, Egger M, Smith GD (2001) Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ 323(7304):101–105CrossRef

Titel: Effects of products designed to modulate the gut microbiota on hyperlipidaemia
verfasst von: Xilong Deng
Jie Ma
Meiting Song
Ye Jin
Cheng Ji
Weihong Ge
Changrun Guo
Publikationsdatum: 20.09.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nutrition / Ausgabe 7/2019
Print ISSN: 1436-6207
Elektronische ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-018-1821-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2019

Oral administration of oat beta-glucan preparations of different molecular weight results in regulation of genes connected with immune response in peripheral blood of rats with LPS-induced enteritis

Quantitative assessment of dietary supplement intake in 77,000 French adults: impact on nutritional intake inadequacy and excessive intake

Habitual consumption of soy protein and isoflavones and risk of metabolic syndrome in adults ≥ 40 years old: a prospective analysis of the Korean Multi-Rural Communities Cohort Study (MRCohort)

Effect of industrial trans-fatty acids-enriched diet on gut microbiota of C57BL/6 mice

Sugar-sweetened beverage consumption and incidence of breast cancer: the Seguimiento Universidad de Navarra (SUN) Project